Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recruiting across multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: C. Babis Andreadis | Conditions: Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Status: RECRUITING